(MENAFN- EIN Presswire)
Intestine Cancer Therapeutics Global market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033
The Business Research Company's Intestine Cancer Therapeutics Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033
It will grow to $19.36 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%.” - The Business Research Company
LANDON, GREATER LANDON, UK, August 2, 2024 /EINPresswire / -- The intestine cancer therapeutics market has experienced robust growth in recent years, expanding from $12.8 billion in 2023 to $14 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to advancements in medical research, increased cancer incidence, chemotherapy and radiation therapies, screening and early detection initiatives, genetic and biomarker discoveries.
Strong Future Growth Anticipated
The intestine cancer therapeutics market is projected to continue its strong growth, reaching $19.36 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to immunotherapy advancements, precision medicine and personalized therapies, emerging targeted therapies, integration of artificial intelligence (AI), patient-centric approaches.
Explore Comprehensive Insights Into The Global Intestine Cancer Therapeutics Market With A Detailed Sample Report:
Growth Driver Of The Intestine Cancer Therapeutics Market
The increasing prevalence of hereditary colorectal cancer syndromes is expected to propel the growth of the intestine cancer therapeutics market going forward. Hereditary colorectal cancer syndromes are a group of genetic conditions that increase an individual's risk of developing colorectal cancer (colon or rectum cancer). Hereditary colorectal cancer syndromes play a significant role in intestinal cancer therapeutics, providing information associated with specific genetic mutations that substantially increase the risk of developing colorectal cancer.
Explore The Report Store To Make A Direct Purchase Of The Report:
Major Players And Market Trends
Key players in the intestine cancer therapeutics market include Pfizer Inc., Johnson & Johnson Private Limited, Roche Holding AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company.
Major companies operating in the intestine cancer therapeutics market are developing innovative products such as Lonsurf and getting approvals to meet larger customer bases, more sales, and increased revenue. LONSURF is a combination of two drugs, trifluridine and tipiracil, for treating adult patients with metastatic colorectal cancer.
Segments:
1) By Treatment Type: Immunotherapy, Chemotherapy, Other Treatments
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By Application: Hospitals, Homecare, Specialty Centers, Other Applications
Geographical Insights: Asia-Pacific Leading The Market
Asia-Pacific was the largest region in the intestine cancer therapeutics market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the intestine cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intestine Cancer Therapeutics Market Definition
Intestine cancer therapeutics refer to the various treatment options available for small intestine and colorectal cancer that affect the digestive system. These treatments aim to remove or manage cancerous cells and improve patient outcomes. The specific treatment plan will depend on the stage of the cancer, the patient's overall health, and other factors.
Intestine Cancer Therapeutics Global Market Report 2024 from The Business Research Company covers the following information:
.Market size data for the forecast period: Historical and Future
.Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
.Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Trends, opportunities, strategies and so much more.
The Intestine Cancer Therapeutics Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on intestine cancer therapeutics market size, intestine cancer therapeutics market drivers and trends, intestine cancer therapeutics market major players, intestine cancer therapeutics competitors' revenues, intestine cancer therapeutics market positioning, and intestine cancer therapeutics market growth across geographies. The intestine cancer therapeutics market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.
Browse Through More Similar Reports By The Business Research Company:
Anti-Inflammatory Therapeutics Global Market Report 2024
report/anti-inflammatory-therapeutics-global-market-report
Small Cell Lung Cancer Therapeutics Global Market Report 2024
report/small-cell-lung-cancer-therapeutics-global-market-report
Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2024
report/duchenne-muscular-dystrophy-dmd-therapeutics-global-market-report
About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.
Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Oliver Guirdham
The Business Research Company
+44 20 7193 0708
...
Visit us on social media:
Facebook
X
LinkedIn
MENAFN02082024003118003196ID1108510210